Search

Search Results

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2129

  PDF: 730

  HTML: 1628

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  2789

  PDF: 1004

  HTML: 5518

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4307

  PDF: 1755

  HTML: 1106

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1466

  PDF: 1136

  HTML: 269

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  1959

  PDF: 743

  HTML: 694

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2100

  PDF: 1683

  HTML: 374

• Pseudo-differentiation syndrome

  Dina Khalaf, Fathi Jehani

  e2011061

  2011-12-15

  https://doi.org/10.4084/mjhid.2011.061

  1339

  PDF: 656

  HTML: 10846

  Figure 1: peripheral blood showing myeloblasts with auer rods: 117

  Figure 2: CXR upon presentation to the hospital- no infiltrates nor consolidation changes: 102

  Figure 3: CXR showing pulmonary infiltartes with consolidation: 136

  Figure 4: CXR after starting steroid therapy- where the infiltrates have melted away: 109

  Figure 5: barograph showing the rising TLC ad ANC values- associated with worsening symptoms and increasing pulmonary infiltrates in CXR: 118

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4161

  PDF: 1448

  HTML: 590

• 5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature

  Mariangela Greco, Marianna Criscuolo, Luana Fianchi, Livio Pagano, Maria Teresa Voso

  e2011011

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.011

  1579

  PDF: 757

  HTML: 1109

• ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME

  Teresa L Field, Claudio Anasetti

  e2010019

  2010-07-19

  https://doi.org/10.4084/mjhid.2010.019

  1308

  PDF: 660

  HTML: 1184

• Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited

  IOANNIS KOTSIANIDIS

  e2019045

  2019-06-25

  https://doi.org/10.4084/mjhid.2019.045

  1078

  PDF: 840

  HTML: 236

• TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE

  Maël Heiblig, Mohamed Elhamri, Isabelle Tigaud, Adriana Plesa, Fiorenza Barraco, Hélène Labussière, Sophie Ducastelle, Mauricette Michallet, Franck Nicolini, Claudiu Plesa, Eric Wattel, Gilles Salles, Xavier Thomas

  e2016009

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.009

  7310

  PDF: 1491

  HTML: 1644

• Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF

  Wen Yao, Xinchen Fang, Peng Jiang, Juan Tong, Liangquan Geng, Xiaoyu Zhu, Baolin Tang, Xiang Wan, Kaidi Song, Lei Zhang, Ping Qiang, Guangyu Sun, Yongsheng Han, Huilan Liu, Zimin Sun

  e2022025

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.025

  1752

  PDF: 563

  HTML: 278

• A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management

  Elena Elli, Caterina Cecchetti, Angelo Belotti, Lorenza Borin, Enrico Maria Pogliani

  e2012017

  2012-03-13

  https://doi.org/10.4084/mjhid.2012.017

  1165

  PDF: 656

  HTML: 747

• DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES

  Prof. Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso

  e2022030

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.030

  1362

  HTML: 389

  PDF: 814

• THROMBOCYTOPENIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - STILL AN UNSOLVED PROBLEM

  May Basood, Howard S. Oster, Moshe Mittelman

  e2018046

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.046

  3047

  PDF: 1379

  HTML: 541

• Clinical and Prognostic Features in a Young Adult Patient with de novo Myelodysplastic Syndrome presenting t(11;16) (q23; q24)

  Viviane Lamim Lovatel, Luize Otero, Ercole Pietro Orlando, Claudia Diniz, Filipe Vicente dos Santos-Bueno, Bruno Almeida Lopes, Elaiza Almeida Antônio de Kós, Monica Kopischitz Praxedes Lusis, Eliana Abdelhay, Teresa de Souza Fernandez

  e2022013

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.013

  1091

  PDF: 548

  HTML: 218

• The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones

  Antonio Cristiano, Raffaele Palmieri, Emiliano Fabiani, Tiziana Ottone, Mariadomenica Divona, Arianna Savi, Francesco Buccisano, Luca Maurillo, Corrado Tarella, William Arcese, Maria Teresa Voso

  e2022041

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.041

  1222

  PDF: 756

  HTML: 312

• THE CHALLENGE OF AML IN OLDER PATIENTS

  Alan K Burnett

  e2013038

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.038

  2170

  PDF: 945

  HTML: 2155

• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.

  Elisabetta Metafuni, Patrizia Chiusolo, Luca Laurenti, Federica Sorà, Sabrina Giammarco, Andrea Bacigalupo, Giuseppe Leone, Simona Sica

  e2018005

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.005

  4167

  PDF: 1067

  HTML: 1260

• EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA

  Linjuan Xu

  e2025058

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.058

  1449

  PDF: 757

  Suppl. Files: 320

  Html: 133

• HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE

  Giovanna Cannas, Solene Poutrel, Xavier Thomas

  e2017015

  2017-02-15

  https://doi.org/10.4084/mjhid.2017.015

  3920

  PDF: 1160

  HTML: 1650

• SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib

  Matteo Molica

  e2024079

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.079

  934

  PDF: 510

  HTML: 191

• PHYSICIAN’S ATTITUDE TOWARDS TREATMENT OF OLDER PATIENTS AND THE CHOICE OF THERAPY

  Felicetto Ferrara

  e2013025

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.025

  2345

  PDF: 780

  HTML: 1846

• HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

  Mazyar Shadman, Joachim Deeg

  e2014056

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.056

  2004

  PDF: 758

  HTML: 3113

• PATHOPHISIOLOGY OF SICKLE CELL DISEASE AND NEW DRUGS FOR THE TREATMENT

  Lucia De Franceschi

  e2009024

  2009-12-26

  1052

  PDF: 652

  HTML: 11078

• COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES

  M. Domenica Cappellini, Khaled M. Musallam, Alessia Marcon, Ali Taher

  e2009029

  2009-12-28

  1097

  PDF: 485

  HTML: 8162

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2441

  PDF: 783

  HTML: 1735

• Leukemia cutis in a patient with acute myeloid leukemia undergoing Azacitidine-Venetoclax: case presentation and review of the literature

  Elisa Buzzatti, Cristina Mauro, Caterina Botti, Roberta Presicci, Giovangiacinto Paterno, Raffaele Palmieri, Carmelo Gurnari, Flavia Mallegni, Elisa Meddi, Federico Moretti, Lucia Cardillo, Valeria Mezzanotte, Kristian Taka, Lucrezia De Marchi, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe

  e2025013

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.013

  965

  PDF: 1094

  HTML: 114

• THALASSEMIA AND VENOUS THROMBOEMBOLISM

  Julien Succar, Khaled M. Musallam, Ali T Taher

  e2011025

  2011-05-25

  https://doi.org/10.4084/mjhid.2011.025

  2915

  PDF: 1019

  HTML: 4583

• Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

  Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain

  e2010012

  2010-05-31

  https://doi.org/10.4084/mjhid.2010.012

  1060

  PDF: 686

  HTML: 345

• RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES

  Julie Schanz, Friederike Braulke, Detlef Haase

  e2015034

  2015-04-23

  https://doi.org/10.4084/mjhid.2015.034

  3752

  PDF: 1649

  HTML: 11571

  Figures Haase: 195

• Is there a better therapeutic time window from diagnosis to treatment elderly acute myeloid leukemia patients receiving hypomethylating agents?

  Salvatore Perrone

  e2024055

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.055

  568

  PDF: 796

  HTML: 96

• MOLECULAR HETEROGENEITY IN ACUTE PROMYELOCYTIC LEUKEMIA - A SINGLE CENTRE EXPERIENCE FROM INDIA

  Nikhil Rabade, Goutham Raval, Shruti Chaudhary, PG Subramanian, Rohan Kodgule, Swapnali Joshi, Prashant Tembhare, Hasmukh Jain, Manju Sengar, Syed Hasan K, Pratibha Amare Kadam, Dhanalaxmi Shetty, Gaurav Narula, Shripad Banavali, Sumeet Gujral, Nikhil Patkar

  e2018002

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.002

  3610

  PDF: 1190

  HTML: 1081

• Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination

  Daniela Taurino, Marco Frigeni, Anna Grassi, Gianluca Cavallaro, Silvia Salmoiraghi, Orietta Spinelli, Alessandro Rambaldi, Federico Lussana

  e2021057

  2021-08-28

  https://doi.org/10.4084/MJHID.2021.057

  1197

  PDF: 494

  HTML: 168

• Myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity

  Eleftheria Lamprianidou, Chryssoula Kordella, Menelaos Papoutselis, Zoi Bezyrgiannidou, Evangelia Nakou, Spyros Papamichos, Emmanouil Spanoudakis, Andreas Giannopoulos, Katerina Zoi, Ioannis Kotsianidis

  e2017066

  2017-11-01

  https://doi.org/10.4084/mjhid.2017.066

  2270

  PDF: 772

  HTML: 817

• LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML

  Xavier Thomas, Marica Laurino, sandrine loron, marie-virginie larcher, gaëlle fossard, mohamed elhamri, alexandre deloire, marie balsat, fiorenza barraco, hélène labussière, sophie ducastelle, myriam renault, eric wattel, maël heiblig, gilles salles

  e2020020

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.020

  1707

  PDF: 1159

  HTML: 244

• AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH.

  Pasquale Niscola

  e2014020

  2014-02-16

  https://doi.org/10.4084/mjhid.2014.020

  1645

  PDF: 889

  HTML: 2781

• Should every patient with MDS get iron chelation – probably yes.

  Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh

  e2017055

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.055

  2308

  PDF: 944

  HTML: 377

• Morphologic leukemia-free state after venetoclax-based therapy in acute myeloid leukemia is associated with high relapse despite preserved short-term survival

  Kenta Motegi

  e2026048

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.048

  184

  PDF: 200

  HTML: 14